![]() |
市场调查报告书
商品编码
1467848
2024-2032 年静脉治疗和静脉通路市场(按类型、应用、最终用户和地区)Intravenous Therapy and Vein Access Market by Type, Application, End User, and Region 2024-2032 |
2023 年,全球静脉 (IV) 治疗和静脉通路市场规模达到 251 亿美元。 展望未来, IMARC Group预计到 2032 年,市场规模将达到 382 亿美元,2024 年复合年增长率 (CAGR) 为 4.64%。 2032.慢性病盛行率不断上升、交通事故发生率不断上升,以及消费者对静脉注射疗法益处的认识不断提高,是推动市场发展的一些关键因素。
静脉 (IV) 治疗是一种医疗程序,涉及透过静脉将液体、药物和营养物质直接注射到血液中。此技术通常用于医院、诊所和其他医疗机构来治疗各种病症和疾病。静脉通路是进入静脉进行静脉注射治疗的过程。医疗保健专业人员通常使用针刺穿皮肤并进入静脉,由于静脉细小或受损、脱水和肥胖等因素,这对某些患者来说可能具有挑战性。静脉注射疗法有多种类型,包括用于脱水的盐水溶液、用于感染的抗生素以及用于癌症治疗的化学治疗。除了治疗疾病外,静脉注射疗法还可以用于预防措施,例如接种疫苗和维生素。
癌症、糖尿病和自体免疫疾病等慢性病和生活方式疾病的盛行率不断上升,需要长期用药和监测,这主要推动了全球静脉 (IV) 治疗和静脉通路市场的成长。除此之外,道路事故发生率的上升和创伤病例的激增也促进了市场的成长。此外,消费者对静脉注射治疗和静脉通路益处的认识不断提高,以及重症监护治疗的兴起,为市场带来了有利可图的成长机会。与此一致的是,对微创手术的偏好的转变是另一个重要的成长诱导因素。除此之外,医疗保健行业的许多技术进步减少了所需的时间和精力,降低了感染风险并提高了手术的准确性,正在为市场创造积极的前景。同时,对创新疗法、药物和设备的研发(R&D)活动的大量投资也有助于市场扩张。此外,医疗保健支出的增加、医院数量的增加、家庭医疗保健的广泛采用以及老年人口的扩大正在加强市场的成长。
The global intravenous (IV) therapy and vein access market size reached US$ 25.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 38.2 Billion by 2032, exhibiting a growth rate (CAGR) of 4.64% during 2024-2032. The growing prevalence of chronic diseases, the increasing incidences of road accidents, and the rising consumer awareness about the benefits of IV therapy represent some of the key factors driving the market.
Intravenous (IV) therapy is a medical procedure that involves administering fluids, medications, and nutrition directly into the bloodstream through a vein. This technique is commonly used in hospitals, clinics, and other healthcare facilities to treat various conditions and illnesses. Vein access is the process of entering a vein in order to administer IV therapy. A healthcare professional typically uses a needle to puncture the skin and access a vein, which can be challenging in some patients due to factors such as small or damaged veins, dehydration, and obesity. There are several types of IV therapy, including saline solutions for dehydration, antibiotics for infections, and chemotherapy for cancer treatment. In addition to treating medical conditions, IV therapy can also be used for preventative measures, such as receiving vaccinations and vitamins.
The increasing prevalence of chronic and lifestyle diseases, such as cancer, diabetes, and autoimmune diseases that require long-term medication and monitoring, is primarily driving the global intravenous (IV) therapy and vein access market growth. Besides this, the rising incidences of road accidents and the surging number of trauma cases are contributing to the market growth. Moreover, the escalating consumer awareness about the benefits of IV therapy and vein access and the rise in critical care therapies are presenting remunerative growth opportunities for the market. In line with this, the shifting preference for minimally invasive procedures is acting as another significant growth-inducing factor. In addition to this, numerous technological advancements in the healthcare industry to reduce the needed time and effort, lower the risk of infection, and improve the accuracy of the procedure are creating a positive outlook for the market. Concurrent with this, extensive investments in research and development (R&D) activities for innovating new therapies, drugs, and devices are aiding in market expansion. Furthermore, the increasing healthcare expenditure, rise in the number of hospitals, the widespread adoption of home healthcare, and the expanding geriatric population are strengthening the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global intravenous (IV) therapy and vein access market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on type, application, and end user.
Implantable Ports
Intravenous Catheters
Hypodermic Needles
Infusion Pumps
Others
The report has provided a detailed breakup and analysis of the intravenous (IV) therapy and vein access market based on the type. This includes implantable ports, intravenous catheters, hypodermic needles, infusion pumps, and others. According to the report, intravenous catheters represented the largest segment.
Nutrition and Buffer Solution
Volume Expander
Medication Administration
Blood Based Products
A detailed breakup and analysis of the intravenous (IV) therapy and vein access market based on the application has also been provided in the report. This includes nutrition and buffer solution, volume expander, medication administration, and blood-based products. According to the report, medication administration accounted for the largest market share.
Hospitals
Ambulatory Surgical Center
Clinics
The report has provided a detailed breakup and analysis of the intravenous (IV) therapy and vein access market based on the end user. This includes hospitals, ambulatory surgical centers, and clinics. According to the report, hospitals represented the largest segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for intravenous (IV) therapy and vein access. Some of the factors driving the North America intravenous (IV) therapy and vein access market included the growing prevalence of chronic diseases, the increasing number of road accidents, and the expanding geriatric population.
The report has also provided a comprehensive analysis of the competitive landscape in the global intravenous (IV) therapy and vein access market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AngioDynamics Inc., B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, Cardinal Health Inc., Fresenius SE & Co. KGaA, ICU Medical Inc., Medtronic plc, Tekni-Plex Inc., Teleflex Incorporated, Terumo Corporation, Vygon SAS, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.